


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (Currently amended) A combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer, comprising two separate preparations:

(a) *—a first preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one compound of general formula I:



{wherein R¹ and R² each independently represent:

a hydrogen atom, lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, or heterocyclic group (wherein the lower alkyl, the lower alkenyl, the lower alkynyl, the aryl, the aralkyl, and the heterocyclic group may each have one to five of the same or different substituents selected from the group consisting of

carboxyl, carbamoyl, sulfo, amino, cyano, mono-lower alkylamino, di-lower alkylamino, hydroxyl, and a halogen atom);

or a group of formula $-Y-R^3$ {wherein Y represents carbonyl, thiocarbonyl, or sulfonyl, and R^3 represents a hydrogen atom, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aralkyl, lower alkoxy, hydrazino, amino, arylamino, carbamoyl, or heterocyclic group (wherein the lower alkyl, the cycloalkyl, the cycloalkyl-lower alkyl, the aryl, the aralkyl, and the heterocyclic group may each have one to four of the same or different substituents selected from the group consisting of a halogen atom, optionally protected hydroxyl, amino, carboxyl, carbamoyl, cyano, and lower alkoxycarbonyl in which the amino and the carbamoyl may each be further mono- or di-substituted by lower alkyl optionally substituted by a substituent or substituents selected from the group consisting of a halogen atom, hydroxyl, amino, carboxyl, carbamoyl, and lower alkoxycarbonyl)}; or

a group of formula $-(CH_2)_m-R^4$ {wherein R^4 is pyridyl, furyl, or thienyl (wherein the pyridyl, the furyl, and the thienyl may each have one or two substituents selected from the group consisting of hydroxyl, lower alkoxy, hydroxy-lower alkyl, and hydroxy-lower alkenyl), and m is an integer of 1 to 3},

R^1 and R^2 are combined together to represent lower alkylidene (wherein the lower alkylidene may have one to four of the same or different substituents selected from the group

consisting of amino, mono-lower alkylamino, di-lower alkylamino, hydroxyl, carboxyl, and sulfo), or

R^1 and R^2 , together with the nitrogen atom to which they bind, form heterocyclic group (wherein the heterocyclic group may have, on said ring, lower alkyl optionally substituted by a group or groups selected from the group consisting of amino, hydroxyl, carboxyl, and sulfo),

G represents a pentosyl or hexosyl; and

X^1 and X^2 each independently represent a hydrogen atom, a halogen atom, amino, mono-lower alkylamino, di-lower alkylamino, hydroxyl, lower alkoxy, aralkoxy, carboxyl, lower alkoxycarbonyl, or lower alkyl+

or a pharmaceutically acceptable salt thereof; and

(b) *—a second preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one antitumor agent selected from the group consisting of antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, plant-derived antitumor agents, antitumor platinum-complex compounds, antitumor camptothecin derivatives, antitumor tyrosine kinase inhibitors, monoclonal antibodies, interferons, biological response modifiers, and other antitumor agents or a pharmaceutically acceptable salt thereof

(wherein the antitumor alkylating agents are nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine,

nimustine, or temozolomide,

the antitumor antimetabolites are methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocfosphate, enocitabine, S-1, gemcitabine, or fludarabine,

the antitumor antibiotics are actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, or idarubicin,

the plant-derived antitumor agents are vincristine, vinblastine, vindesine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine,

the antitumor platinum-complex compounds are cisplatin, carboplatin, nedaplatin, or oxaliplatin,

the antitumor camptothecin derivatives are irinotecan, topotecan, or camptothecin,

the antitumor tyrosine kinase inhibitors are Iressa or SU5416,

the monoclonal antibodies are IMC-C225, RhuMabVEGF, or Rituximab,

the interferons are interferon α , interferon α -2a, interferon α -2b, interferon β , interferon γ -1a, or interferon γ -n1,

the biological response modifiers are krestin, lentinan, sizofiran, picibanil, or ubenimex, and


the other antitumor agents are mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, or tretinoin).

Claim 2. (Currently amended) A The combined preparation for simultaneous, separate, or sequential administration in the treatment of cancer of claim 1, comprising ~~two separate preparations:~~ the first preparation and the second preparation,


~~* a preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one compound of general formula I as defined in Claim 1 (wherein R^1 , R^2 , R^3 , R^4 , m, Y, G, X^1 , and X^2 are the same as defined in Claim 1) or a pharmaceutically acceptable salt thereof, and~~

~~* a preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one~~ wherein the antitumor agent described in the paragraph (b) is selected from the group consisting of: 5-fluorouracil; S-1; gemcitabine; doxorubicin and etoposide; docetaxel and paclitaxel; cisplatin, carboplatin, and oxaliplatin; irinotecan, topotecan, and camptothecin; Iressa and SU5416; and IMC-C225 and RhuMabVEGF or a pharmaceutically acceptable salt thereof (wherein, if said preparation contains 5-fluorouracil, it may further contain leucovorin or may be combined with a separate leucovorin preparation).

Claim 3. (Currently amended) A The combined preparation as defined in Claim 2, wherein G is a group of formula:



or




wherein R⁵ represents a hydrogen atom or lower alkyl, and R⁶ represents hydroxyl or amino.

Claim 4. (Currently amended) A The combined preparation as claimed in Claim 3, wherein X¹ and X² bind to the indolopyrrolocarbazole ring at the 1- or 2-position and at the 10- or 11-position, respectively, and each independently represent a halogen atom, hydroxyl, lower alkoxy, or aralkoxy.

Claim 5. (Currently amended) A The combined preparation as claimed in Claim 4, wherein G is β-D-glucopyranosyl, and X¹ and X² represent hydroxyl bonded to the indolopyrrolocarbazole ring at the 2-position and at the 10-position, respectively.

Claim 6. (Currently amended) A The combined preparation as claimed in Claim 5, wherein R¹ represents a hydrogen atom, and R² represents a group of formula:




Claim 7. (Currently amended) A The combined preparation as claimed in Claim 5, wherein R¹ represents a hydrogen atom, and R² represents -CH₂-R⁴ in which R⁴ represents 6-hydroxymethylpyridin-2-yl.

Claim 8. (Currently amended) A The combined preparation as claimed in Claim 5, wherein R¹ represents a hydrogen atom, and R² represents -CH₂-R⁴ in which R⁴ represents pyridin-4-yl.

Claim 9. (Currently amended) A The combined preparation as claimed in Claim 5, wherein R¹ represents a hydrogen atom, and R² represents -CH₂-R⁴ in which R⁴ represents 5-hydroxymethylpyridin-4-yl.

Claim 10. (Currently amended) A The combined preparation as claimed in Claim 1 or 2, wherein the compound of general formula I ~~as defined in Claim 1~~ described in the paragraph (a) is the

compound of formula IA:



Claim 11. (Currently amended) ~~A~~ The combined preparation as claimed in Claim 10, wherein one of or both of the two separate preparations ~~according to Claim 1~~ is/are parenteral preparation(s).

Claim 12. (Currently amended) ~~A~~ The combined preparation as claimed in Claim 11, wherein one of or both of the two separate preparations ~~according to Claim 1~~ is/are an injection or an infusion.

Claim 13. (Currently amended) ~~A~~ The combined preparation as claimed in Claim 12, which is further combined with at least one preparation comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one antitumor agent

selected from the group consisting of antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, plant-derived antitumor agents, antitumor platinum-complex compounds, antitumor camptothecin derivatives, antitumor tyrosine kinase inhibitors, monoclonal antibodies, interferons, biological response modifiers, and other antitumor agents ~~(wherein a definition of each antitumor agent is the same as defined in Claim 1)~~ wherein the antitumor alkylating agents are nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, or temozolomide,

the antitumor antimetabolites are methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, gemcitabine, or fludarabine,

the antitumor antibiotics are actinomycin D, doxorubicin, daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer, or idarubicin,

the plant-derived antitumor agents are vincristine, vinblastine, vindesine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine,

the antitumor platinum-complex compounds are cisplatin, carboplatin, nedaplatin, or oxaliplatin,

the antitumor camptothecin derivatives are irinotecan, topotecan,

or camptothecin,

the antitumor tyrosine kinase inhibitors are Iressa or
SU5416,

the monoclonal antibodies are IMC-C225, RhuMabVEGF, or
Rituximab,

the interferons are interferon α , interferon α -2a,
interferon α -2b, interferon β , interferon γ -1a, or interferon γ -
n1,


the biological response modifiers are krestin, lentinan,
sizofiran, picibanil, or ubenimex, and

the other antitumor agents are mitoxantrone, L-asparaginase,
procarbazine, dacarbazine, hydroxycarbamide, pentostatin, or
tretinoin,

or a pharmaceutically acceptable salt thereof.

Claim 14. (Currently amended) A method for cancer treatment,
comprising simultaneously, separately or sequentially
administering to a cancer patient:

(a) a therapeutically effective amount of at least one compound
of general formula I: ~~as defined in Claim 1 (wherein R^1 , R^2 , R^3 , R^4 , m, Y, G, X^1 , and X^2 are the same as defined in Claim 1)~~



wherein R¹ and R² each independently represent:

a hydrogen atom, lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, or heterocyclic group (wherein the lower alkyl, the lower alkenyl, the lower alkynyl, the aryl, the aralkyl, and the heterocyclic group may each have one to five of the same or different substituents selected from the group consisting of carboxyl, carbamoyl, sulfo, amino, cyano, mono-lower alkylamino, di-lower alkylamino, hydroxyl, and a halogen atom);

or a group of formula -Y-R³ wherein Y represents carbonyl, thiocarbonyl, or sulfonyl, and R³ represents a hydrogen atom, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aralkyl, lower alkoxy, hydrazino, amino, arylamino, carbamoyl, or heterocyclic group (wherein the lower alkyl, the cycloalkyl, the cycloalkyl-lower alkyl, the aryl, the aralkyl, and the heterocyclic group may each have one to four of the same or different substituents selected from the group consisting of a

halogen atom, optionally protected hydroxyl, amino, carboxyl, carbamoyl, cyano, and lower alkoxy carbonyl in which the amino and the carbamoyl may each be further mono- or di-substituted by lower alkyl optionally substituted by a substituent or substituents selected from the group consisting of a halogen atom, hydroxyl, amino, carboxyl, carbamoyl, and lower alkoxy carbonyl); or

a group of formula $-(CH_2)_m-R^4$ wherein R^4 is pyridyl, furyl, or thienyl (wherein the pyridyl, the furyl, and the thienyl may each have one or two substituents selected from the group consisting of hydroxyl, lower alkoxy, hydroxy-lower alkyl, and hydroxy-lower alkenyl), and m is an integer of 1 to 3,

R^1 and R^2 are combined together to represent lower alkylidene (wherein the lower alkylidene may have one to four of the same or different substituents selected from the group consisting of amino, mono-lower alkylamino, di-lower alkylamino, hydroxyl, carboxyl, and sulfo), or

R^1 and R^2 , together with the nitrogen atom to which they bind, form heterocyclic group (wherein the heterocyclic group may have, on said ring, lower alkyl optionally substituted by a group or groups selected from the group consisting of amino, hydroxyl, carboxyl, and sulfo),

G represents a pentosyl or hexosyl; and

X^1 and X^2 each independently represent a hydrogen atom, a halogen atom, amino, mono-lower alkylamino, di-lower alkylamino,

hydroxyl, lower alkoxy, aralkoxy, carboxyl, lower alkoxy carbonyl
or a pharmaceutically acceptable salt thereof; ~~in~~
~~combination with~~
and

(b) a therapeutically effective amount of at least one
antitumor agent selected from the group consisting of antitumor
alkylating agents, antitumor antimetabolites, antitumor
antibiotics, plant-derived antitumor agents, antitumor platinum-
complex compounds, antitumor camptothecin derivatives, antitumor
tyrosine kinase inhibitors, monoclonal antibodies, interferons,
biological response modifiers, and other antitumor agents
~~(wherein a definition of each antitumor agent is the same as~~
~~defined in Claim 1)~~

(wherein the antitumor alkylating agents are nitrogen
mustard N-oxide, cyclophosphamide, ifosfamide, melphalan,
busulfan, mitobronitol, carboquone, thiotepa, ranimustine,
nimustine, or temozolomide,

the antitumor antimetabolites are methotrexate, 6-
mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur,
doxifluridine, carmofur, cytarabine, cytarabine ocfosfate,
enocitabine, S-1, gemcitabine, or fludarabine,

the antitumor antibiotics are actinomycin D, doxorubicin,
daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin
C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer,
or idarubicin,

the plant-derived antitumor agents are vincristine, vinblastine, vindesine, etoposide, sobuzoxane, docetaxel, paclitaxel, or vinorelbine,

the antitumor platinum-complex compounds are cisplatin, carboplatin, nedaplatin, or oxaliplatin,

the antitumor camptothecin derivatives are irinotecan, topotecan, or camptothecin,

the antitumor tyrosine kinase inhibitors are Iressa or SU5416,

the monoclonal antibodies are IMC-C225, RhuMabVEGF, or Rituximab,

the interferons are interferon α , interferon α -2a, interferon α -2b, interferon β , interferon γ -1a, or interferon γ -n1,

the biological response modifiers are krestin, lentinan, sizofiran, picibanil, or ubenimex, and

the other antitumor agents are mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, or tretinoin)


or a pharmaceutically acceptable salt thereof.

Claim 15. (Currently amended) A ~~The method for cancer treatment, comprising administering to a cancer patient:~~


~~(a) a therapeutically effective amount of at least one compound of general formula I defined in Claim 1 (wherein R^1 , R^2 , R^3 , R^4 ,~~

~~m, Y, G, X¹, and X² are the same as defined in Claim 1) or a pharmaceutically acceptable salt thereof, in combination with~~
~~(b) a therapeutically effective amount of at least one~~
antitumor agent of claim 14, wherein the antitumor agent
described in the paragraph (b) is selected from the group
 consisting of: 5-fluorouracil; S-1; gemcitabine; doxorubicin and
 etoposide; docetaxel and paclitaxel; cisplatin, carboplatin, and
 oxaliplatin; irinotecan, topotecan, and camptothecin; Iressa and
 SU5416; and IMC-C225 and RhuMabVEGF or a pharmaceutically
 acceptable salt thereof (wherein, if the compound of general
 formula I as defined ~~in Claim 1~~ herein is combined with 5-
 fluorouracil, leucovorin may be further combined).

Claim 16. (Currently amended) A The method as claimed in Claim
 15, wherein G is a group of formula:



or




wherein R⁵ represents a hydrogen atom or lower alkyl, and R⁶ represents hydroxyl or amino.

Claim 17. (Currently amended) A The method as claimed in Claim 16, wherein X¹ and X² bind to the indolopyrrolocarbazole ring at the 1- or 2-position and at the 10- or 11-position, respectively, and each independently represent a halogen atom, hydroxyl, lower alkoxy, or aralkoxy.

Claim 18. (Currently amended) A The method as claimed in Claim 17, wherein G is β -D-glucopyranosyl, and X¹ and X² represent hydroxyl bonded to the indolopyrrolocarbazole ring at the 2-position and at the 10-position, respectively.

Claim 19. (Currently amended) A The method as claimed in Claim 18, wherein R¹ represents a hydrogen atom, and R² represents a group of formula:




Claim 20. (Currently amended) A The method as claimed in Claim 18, wherein R¹ represents a hydrogen atom, and R² represents -CH₂-R⁴ in which R⁴ represents 6-hydroxymethylpyridin-2-yl.

Claim 21. (Currently amended) A The method as claimed in Claim 18, wherein R^1 represents a hydrogen atom, and R^2 represents $-CH_2-R^4$ in which R^4 represents pyridin-4-yl.

Claim 22. (Currently amended) A The method as claimed in Claim 18, wherein R^1 represents a hydrogen atom, and R^2 represents $-CH_2-R^4$ in which R^4 represents 5-hydroxymethylpyridin-4-yl.

Claim 23. (Currently amended) A The method as claimed in Claim 14 or 15, wherein the compound of general formula I ~~as defined in Claim 1~~ described in the paragraph (a) is the compound of formula IA:



Claim 24. (Cancelled).

Claim 25. (Cancelled).

Claim 26. (Cancelled).

Claim 27. (Cancelled).

Claim 28. (Cancelled).

Claim 29. (Cancelled).

Claim 30. (Cancelled).


Claim 31. (Cancelled).

Claim 32. (Cancelled).

Claim 33. (Cancelled).

Claim 34. (Currently amended) A pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier or diluent, ~~at least one compound of general formula I as defined above (wherein R^1 , R^2 , R^3 , R^4 , m, Y, G, X^1 , and X^2 are the same as defined above) or a pharmaceutically acceptable salt thereof; and at least one antitumor agent selected from the group consisting of antitumor alkylating agents, antitumor antimetabolites, antitumor antibiotics, plant-derived antitumor agents, antitumor platinum-complex compounds, antitumor camptothecin derivatives, antitumor tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other antitumor agents (wherein a definition of each antitumor agent is the same as defined above) or a pharmaceutically acceptable salt thereof~~

(a) a therapeutically effective amount of at least one compound of general formula I:



wherein R^1 and R^2 each independently represent:

a hydrogen atom, lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, or heterocyclic group (wherein the lower alkyl, the lower alkenyl, the lower alkynyl, the aryl, the aralkyl, and the heterocyclic group may each have one to five of the same or different substituents selected from the group consisting of carboxyl, carbamoyl, sulfo, amino, cyano, mono-lower alkylamino, di-lower alkylamino, hydroxyl, and a halogen atom);

or a group of formula $-Y-R^3$ wherein Y represents carbonyl, thiocarbonyl, or sulfonyl, and R^3 represents a hydrogen atom, lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aralkyl, lower alkoxy, hydrazino, amino, arylamino, carbamoyl, or heterocyclic group (wherein the lower alkyl, the cycloalkyl, the cycloalkyl-lower alkyl, the aryl, the aralkyl, and the heterocyclic group may each have one to four of the same or different substituents selected from the group consisting of a

halogen atom, optionally protected hydroxyl, amino, carboxyl, carbamoyl, cyano, and lower alkoxy carbonyl in which the amino and the carbamoyl may each be further mono- or di-substituted by lower alkyl optionally substituted by a substituent or substituents selected from the group consisting of a halogen atom, hydroxyl, amino, carboxyl, carbamoyl, and lower alkoxy carbonyl); or

a group of formula $-(CH_2)_m-R^4$ wherein R^4 is pyridyl, furyl, or thienyl (wherein the pyridyl, the furyl, and the thienyl may each have one or two substituents selected from the group consisting of hydroxyl, lower alkoxy, hydroxy-lower alkyl, and hydroxy-lower alkenyl), and m is an integer of 1 to 3,

R^1 and R^2 are combined together to represent lower alkylidene (wherein the lower alkylidene may have one to four of the same or different substituents selected from the group consisting of amino, mono-lower alkylamino, di-lower alkylamino, hydroxyl, carboxyl, and sulfo), or

R^1 and R^2 , together with the nitrogen atom to which they bind, form heterocyclic group (wherein the heterocyclic group may have, on said ring, lower alkyl optionally substituted by a group or groups selected from the group consisting of amino, hydroxyl, carboxyl, and sulfo),

G represents a pentosyl or hexosyl; and

X^1 and X^2 each independently represent a hydrogen atom, a halogen atom, amino, mono-lower alkylamino, di-lower alkylamino,

hydroxyl, lower alkoxy, aralkoxy, carboxyl, lower alkoxycarbonyl
or a pharmaceutically acceptable salt thereof; and

(b) a therapeutically effective amount of at least one
antitumor agent selected from the group consisting of antitumor
alkylating agents, antitumor antimetabolites, antitumor
antibiotics, plant-derived antitumor agents, antitumor platinum-
complex compounds, antitumor camptothecin derivatives, antitumor
tyrosine kinase inhibitors, monoclonal antibodies, interferons,
biological response modifiers, and other antitumor agents or a
pharmaceutically acceptable salt thereof

(wherein the antitumor alkylating agents are nitrogen
mustard N-oxide, cyclophosphamide, ifosfamide, melphalan,
busulfan, mitobronitol, carboquone, thiotepa, ranimustine,
nimustine, or temozolomide,

the antitumor antimetabolites are methotrexate, 6-
mercaptopurine riboside, mercaptopurine, 5-fluorouracil, tegafur,
doxifluridine, carmofur, cytarabine, cytarabine ocfosfate,
enocitabine, S-1, gemcitabine, or fludarabine,

the antitumor antibiotics are actinomycin D, doxorubicin,
daunorubicin, neocarzinostatin, bleomycin, peplomycin, mitomycin
C, aclarubicin, pirarubicin, epirubicin, zinostatin stimalamer,
or idarubicin,

the plant-derived antitumor agents are vincristine,
vinblastine, vindesine, etoposide, sobuzoxane, docetaxel,
paclitaxel, or vinorelbine,

the antitumor platinum-complex compounds are cisplatin, carboplatin, nedaplatin, or oxaliplatin,

the antitumor camptothecin derivatives are irinotecan, topotecan, or camptothecin,

the antitumor tyrosine kinase inhibitors are Iressa or SU5416,

the monoclonal antibodies are IMC-C225, RhuMabVEGF, or Rituximab,

the interferons are interferon α , interferon α -2a, interferon α -2b, interferon β , interferon γ -1a, or interferon γ -n1,

the biological response modifiers are krestin, lentinan, sizofiran, picibanil, or ubenimex, and the other antitumor agents are mitoxantrone, L-asparaginase, procarbazine, dacarbazine, hydroxycarbamide, pentostatin, or tretinoin).

Claim 35. (Currently amended) A The pharmaceutical composition of claim 34 comprising, in combination with a pharmaceutically acceptable carrier or diluent, at least one compound of general formula I as defined above (wherein R^1 , R^2 , R^3 , R^4 , m, Y, G, X^1 , and X^2 are the same as defined above) or a pharmaceutically acceptable salt thereof, and wherein the at least one antitumor agent described in the paragraph (b) is selected from the group consisting of 5-fluorouracil; S-1; gemcitabine hydrochloride; doxorubicin hydrochloride and etoposide; docetaxel hydrate and

paclitaxel; cisplatin, carboplatin, and oxaloplatin; irinotecan, topotecan, and camptothecin; Iressa and SU5416; IMC-C225 and RhuMabVEGF or a pharmaceutically acceptable salt thereof (wherein, if said composition contains the compound of general formula I and 5-fluorouracil, it may further contain leucovorin).